Form 4 for TNGX Tango Therapeutics, Inc.
Accepted 2026-04-16 20:14:04 ET · period of report 2026-04-15 · accession 0001193125-26-159747 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-16 20:14 | 2026-04-15 | TNGX | Crystal Adam | Pres, R, D | M - OptEx | $5.20 | +38.5K | 151.1K | +34% | +$200.0K |
| DT | 2026-04-16 20:14 | 2026-04-15 | TNGX | Crystal Adam | Pres, R, D | S - Sale+OE | $25.00 | -38.5K | 112.6K | -25% | -$961.5K |
| DT | 2026-04-16 20:14 | 2026-04-15 | TNGX | Crystal Adam | Pres, R, D | M - OptEx | $0.00 | -38.5K | 395.0K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-15 | M | A | 38,460 | $5.20 | 151,082 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
| 2 | Common | Common Stock | 2026-04-15 | S | D | 38,460 | $25.00 | 112,622 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-04-15 | M | D | 38,460 | $0.00 | 395,040 | D | $5.20 · — to 2033-03-01 | 38,460 Common Stock | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. (F2) This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |